|United States Patent
||October 14, 1997 |
Method of curing AIDS with tetrasilver tetroxide molecular crystal
The diamagnetic semiconducting molecular crystal tetrasilver tetroxide
(Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS
synergistic pathogens and immunity suppressing moieties (ISM) in humans. A
single intravenous injection of the devices is all that is required for efficacy
at levels of about 40 PPM of human blood. The device molecular crystal contains
two mono and two trivalent silver ions capable of "firing" electrons capable of
electrocuting the AIDS virus, pathogens and ISM. When administered into the
bloodstream, the device electrons will be triggered by pathogens, a
proliferating virus and ISM, and when fired will simultaneously trigger a redox
chelation mechanism resulting in divalent silver moieties which chelate and bind
active sites of the entities destroying them. The devices are completely
non-toxic. However, they put stress on the liver causing hepatomegaly, but there
is no loss of liver function.
||Antelman; Marvin S. (Rehovot, IL)
||Antelman Technologies Ltd. (Providence,
||May 31, 1996|
Related U.S. Patent Documents
|Current U.S. Class:
||424/618 ; 514/495|
|Current International Class:
||A61K 33/38 (20060101); A61K
|Field of Search:
References Cited [Referenced
U.S. Patent Documents
"Is The AIDS Virus A Science Fiction?" by Peter H.
Duesberg and Bryan J. Ellison, Policy Review, Summer 1990, pp. 40-51..
Primary Examiner: Hulina; Amy
Attorney, Agent or Firm: Salter & Michaelson
Parent Case Text
This application is a continuation-in-part of patent application Ser.
No. 08/310,859 filed Sep. 22, 1994, now abandoned.
What is claimed is:
1. A method of treating AIDS-afflicted humans
comprising injecting a multitude of tetrasilver tetroxide molecular crystals
into the bloodstream of the human subject.
2. A method for increasing
white blood cell counts in AIDS-afflicted humans comprising injecting a
multitude of tetrasilver tetroxide molecular crystals into the bloodstream of
the human subject.
3. Methods of treating AIDS-affilicted humans
according to claims 1-2 where the concentration of said molecular crystals is
approximately 40 PPM of the total blood weight of the human subject.
BACKGROUND OF THE INVENTION
The present invention relates to the
employment of molecular crystals as anti-AIDS devices, but more particularly to
the molecular crystal semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which
has two monovalent and two trivalent silver ions per molecule, and which through
this structural configuration enables intermolecular electron transfer capable
of killing viruses and binding them to the resulting silver entity so that a
single intravenous injection will completely obliterate acquired immune
deficiency syndrome (AIDS) in humans. Furthermore, said devices are capable of
killing pathogens and purging the bloodstream of immune suppressing moieties
(ISM) whether or not created by the AIDS virus (HIV); so as to restore the
The present invention is based on concepts previously
elucidated in applicant's U.S. Pat. No. 5,336,499 which discloses the
destruction and inhibition of bacteria, algae and the AIDS virus in nutrient
life supporting systems by using said silver oxide devices. Example 3 of said
patent discloses that 18 PPM of said crystal devices could totally suppress the
AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned
patent, further testing revealed complete 100% destruction of the AIDS virus in
vitro at 20 PPM, and the fact that said devices were harmless when ingested and
inhaled, being non-toxic.
Encouraged by these evaluations and successes,
applicant obtained permission to evaluate the crystals in vitro against murine
acquired immune deficiency syndrome (MAIDS). Only one facility in the State of
Israel is licensed for these evaluations, namely, the Kaplan Hospital in
Rehovot, Israel, which is affiliated with the Hebrew University-Hadassah Medical
School where said evaluations were done.
The initial evaluations
entailed experimenting with various silver moieties cited in applicant's
aforementioned patent, concentrations, non-reactive buffers and modes of
administration. After about 18 months of judicious efforts and initial failures,
success was finally achieved in destroying the MAIDS virus in C57BL mice with a
single intravenous injection. The results of this test program comprise Example
5 of U.S. Pat. No. 5,336,499. After success with mice, the inventor was able to
test the efficacy of said devices on two select etiological groups of terminal
AIDS patients in a clinic in Tegucigalpa, Honduras, Central America.
AIDS patients comprised the etiological subgroups, Candidiasis and Wasting
Syndrome. Current indicator diseases for diagnosing AIDS which have been
expanded by the CDC, fall into the following five major categories with the
approximate percent distribution among AIDS patients:
______________________________________ 1. P. carinii pneumonia 51% 2.
Wasting syndrome 19% 3. Candidiasis 13% 4. Kaposi's sarcoma 11% 5. Dementia 6%
This invention concerns itself
with the treatment and cure of candidiasis and wasting syndrome AIDS patients
with Tetrasil*. These two groups account for approximately one third of AIDS
Stedman's Medical Dictionary (Williams & Wilken's 26th Ed.,
1995) defines wasting syndrome "as a condition of 10% weight loss in conjunction
with diarrhea or fever . . . Associated with AIDS (p. 1744)."
The main object of the invention is to provide for a
molecular scale device of a single tetrasilver tetroxide crystalline molecule
capable of restoring the immunity of AIDS afflicted humans of the two AIDS
etiological subgroups, candidiasis and wasting syndrome.
of the invention is to provide for immunity restoration in said AIDS afflicted
humans through a single injection.
Another object of this invention is
to destroy ISM in humans manifesting AIDS diseases of said AIDS etiological
subgroups irrespective as to whether said ISM was HIV induced, since it is known
that humans may manifest AIDS and still be HIV negative, and thus restore the
immune system in said humans.
Another object of this invention is to
destroy the AIDS virus when present in the systems of said AIDS afflicted
SUMMARY OF THE INVENTION
This invention relates to a
molecular scale device not only capable of destroying the AIDS virus, but of
purging the human bloodstream of pathogens and restoring immunity to AIDS
patients of the candidiasis and wasting syndrome categories. Said molecular
device consists of a single crystal of tetrasilver tetroxide (Ag.sub.4 O.sub.4).
The crystal lattice of this molecule has a unique structure since it is a
diamagnetic semiconducting crystal containing two mono and two trivalent silver
ions, which in effect are capable of "firing" electrons under certain conditions
which will destroy AIDS viruses, other pathogens and immune suppressing moieties
(ISM), not only through the electrocution mode, but also by a binding process
which occurs simultaneously with electron firing, namely, binding and chelation
of divalent silver, i.e., the resulting product of the electron transfer redox
that occur when the monovalent silver ions are oxidized and the trivalent ions
are reduced in the crystal. The binding/chelation effect occurs at active sites
of the AIDS virus, pathogens and ISM. Because of the extremely minute size of a
single molecule of this crystal, several million of these devices may be
employed in concert to destroy a virus colony to purge a life support system of
ISM and pathogens with the consumption of only parts per trillion of the crystal
devices. Thus an optimum of 40 PPM of the devices by weight of human blood was
found to be sufficient to completely obliterate AIDS. This concentration is
slightly over double of the optimum concentration recommended in applicant's
aforementioned U.S. patent for the destruction of the human AIDS virus in vitro.
Other details concerning the structure of the crystal and its mechanism against
pathogens, the AIDS virus and ISM would analogously hold here, and have already
been further elucidated in said patent.
The actual destruction of
pathogens, ISM and the AIDS virus is effectuated by injection of a suspension of
these devices in distilled or deionized water with a non-reacting electrolyte
directly, i.e. intravenously, into the bloodstream. A single injection is all
that is required under these conditions. Accordingly, humans injected in this
manner, upon being inspected after three weeks or more had elapsed and compared
with similar humans that had been given placebos, were completely cured of AIDS.
The control group still manifested AIDS. Accordingly, the tetrasilver tetroxide
device performed in concert with and in full conformity with the ultimate
objects of this invention. Furthermore, three out of four wasting syndrome
terminal patients and four out of the five candidiasis terminal patients were
still alive in 1995 after a year and a half had elapsed from their initial
injection. By that time all the AIDS patients had been released from the clinic
and allowed to return home.
Other objects and features of the present
invention shall become apparent to those skilled in the art when the present
invention is considered in view of the accompanying examples. It should, of
course, be recognized that the accompanying examples illustrate preferred
embodiments of the present invention and are not intended as a means of defining
the limits and scope of the present invention.
patients afflicted with AIDS of the candidiasis etiological category were
segregated for Tetrasil treatment. The rationale for selecting them was based on
facts presented in an article by Peter H. Duesberg and Brian J. Ellison entitled
"Is The AIDS Virus A Science Fiction?" (Policy Review, Summer 1990 pp. 40-51).
Only the factual presentations of the article were utilized and the hypothesis
of the authors was ignored. The facts presented in the article related to the
method of selecting AIDS patients based on the five aforementioned etiological
subgroups targeted by the CDC, and the evidence presented, that there is AIDS
without HIV as well as with it so that an anti-viral agent in most instances
will not necessarily restore the immunity system.
Tetrasil were conducted on AIDS patients at Lucha Contra el Sida, Comayaguela,
Honduras. The patients two weeks prior to inoculation were removed from their
AZT, AIDS therapy. Tetrasil was administered at approximately 40 PPM of blood
volume per patient as a suspension in a proprietary buffer solution (pH=6.5),
supplied by Holipharm Corporation.
The results of evaluations with
candidiasis are tabulated in Table I under its disease category. All patients
evaluated were terminal. Some, however, were in moderate (m) condition and
others in poor (p) as designated in the Table. The I and F designations refer to
initial and final values as shown. WBC indicates white cell blood count. The H
column, following CD 8, indicates whether hepatomegaly occurred. This was an
unfortunate consequence of the treatment which resulted in enlarged livers in
all patients except the second one. Despite hepatomegaly, there was no
interference with liver function.
The onset of hepatomegaly was not
spontaneous and varied from patient to patient, being in the range of 4-16 days.
It should also be noted that shortly after injection of Tetrasil there
were indications of fever (symbolized by T in the Ag.sub.4 O.sub.4 column),
sometimes accompanied by fatigue (F). The body temperature was invariably
38.5.degree. C. (101.3.degree. F.). This was indicative of restoration of the
immune response of the body, since normally the body will destroy pathogens when
the immune system is functional by raising the temperature. The patient who
died; first responded favorably to Diflucan, which previously gave no response.
He was cured of his candidiasis, but unfortunately succumbed to his previous
body damage. All the other candidiasis syndrome people who previously did not
respond to the indicated medications subsequently responded after the Tetrasil
treatment. Further evidence of the recovery of the AIDS patients manifested
itself 30 days after the initial injection when white blood cell counts were
taken. They are shown in Table I under the WBC column, which gives the initial
and final WBC. All candidiasis patients showed a dramatic increase in their
white blood cell counts, indicative of the restoration of their immunity
The above protocol of Example 1 was repeated
with AIDS patients exhibiting wasting syndrome. The results of their treatment
are tabulated in Table I under the disease category of said syndrome. It should
be noted that two of the four wasting syndrome patients showed improved white
blood counts. The female patient, whose condition improved from poor and
terminal to be among the living, showed a decrease in the WBC. However, she
showed an increase in body temperature which was indicative of immune response.
The test results indicate that one cannot rely on a single factor to indicate
the demise of AIDS. The usual HIV marker CD 4 initial and final are irrelevant.
ISM suppression appears to be more critical than the destruction of HIV. AIDS
was suppressed, any permanent damage that had been done to the patients in the
course of their succumbing to AIDS was not obviously cured or corrected by said
crystal device treatment, rather said injury persisted and the patient was
improved with respect to AIDS but still suffered from said permanent injury or
impairment previously inflicted.
Response of AIDS Patients to Single 40 PPM Ag.sub.4 O.sub.4 Inoculation Date
Weight DISEASE PATIENT Inoc. WBC CD 4 DEATH Lbs. Group Sex Age Medictn 1994 I F
I F CD 8 H 1944 I F Ag.sub.4 O.sub.4
Candidiasis M p 28 Diflucan 5/5 1,200 4,200 41 -- 221 + 6/11 82 76 T F m 33 "
5/5 6,000 6,700 554 872 394 - 98 98 T F m 33 Ketaconzl 5/27 2,600 3,850 248 181
951 + 123 123 T M p 62 " 6/2 3,300 3,700 89 237 59 + 105 92 F F m 31 Pentamidn
6/2 2,400 3,050 9 181 65 + 121 118 Pain Wasting M m 27 5/27 3,600 4,600 39 14
709 + 119 120 T Syndrome M m 28 5/27 2,750 -- 10 -- 60 + 7/19 121 119 T, F F p
43 5/27 3,600 2,700 68 246 248 + 101 98 T, F M m 19 5/10 3,850 5,400 137 36 48 +
103 106 T, F
As this invention may be embodied in several forms without departing
from the spirit or essential characteristics thereof, the present embodiments
are therefore illustrative and not restrictive, since the scope of the invention
is defined by the appended claims rather than by the description preceding them,
and all changes that fall within the metes and bounds of the claims or that form
their functional as well as conjointly cooperative equivalents, are therefore
intended to be embraced by these claims.
* * * * *
This site was updated March 24th, 2018
and can be found on these major search engines
GOOGLE BING AOL HOT
BOT MSN LYCOS ASK JEEVES MAMMA
CRAWLER ALTA VISTA LOOKSMART
This site is maintained by http://www.ScottNot.com
All Rights Reserved, including copyrights & trademarks 2018 ruvisual.com
The information and articles on this website are given
freely here in this context